Champions Oncology, Inc. (CSBR)
NASDAQ: CSBR · IEX Real-Time Price · USD
5.03
-0.09 (-1.76%)
Apr 17, 2024, 3:03 PM EDT - Market closed
Champions Oncology Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Champions Oncology stock has a target of 7.50, which predicts an increase of 49.11% from the current stock price of 5.03.
Analyst Consensus: Buy
* Price targets were last updated on Sep 22, 2023.
Analyst Ratings
The average analyst rating for CSBR stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|
Strong Buy | 1 | 1 | 1 |
Buy | 0 | 0 | 0 |
Hold | 0 | 1 | 1 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 13, 2024 |
Roth MKM | Roth MKM | Strong Buy Maintains $9 → $7.5 | Strong Buy | Maintains | $9 → $7.5 | +49.11% | Sep 22, 2023 |
Financial Forecast
Revenue This Year
49.82M
from 53.87M
Decreased by -7.51%
Revenue Next Year
54.75M
from 49.82M
Increased by 9.89%
EPS This Year
-0.64
from -0.39
EPS Next Year
-0.35
from -0.64
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 51.3M | 56.4M | 73.1M | 84.0M | 98.7M | 116.5M |
Avg | 49.8M | 54.7M | 71.0M | 81.6M | 95.9M | 113.2M |
Low | 47.9M | 52.6M | 68.2M | 78.4M | 92.2M | 108.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -4.8% | 13.1% | 33.5% | 18.4% | 21.0% | 21.5% |
Avg | -7.5% | 9.9% | 29.7% | 15.0% | 17.5% | 18.0% |
Low | -11.1% | 5.6% | 24.6% | 10.5% | 12.9% | 13.4% |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -0.66 | -0.36 |
Avg | -0.64 | -0.35 |
Low | -0.62 | -0.33 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.